Cargando…
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
Vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for the treatment of several tumor types; however, some tumors show intrinsic resistance to VEGFR inhibitors, and some patients develop acquired resistance to these inhibitors. Therefore, a strategy to overcome VEGFR inhibit...
Autores principales: | Nakagawa, Takayuki, Matsushima, Tomohiro, Kawano, Satoshi, Nakazawa, Youya, Kato, Yu, Adachi, Yusuke, Abe, Takanori, Semba, Taro, Yokoi, Akira, Matsui, Junji, Tsuruoka, Akihiko, Funahashi, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317894/ https://www.ncbi.nlm.nih.gov/pubmed/24689876 http://dx.doi.org/10.1111/cas.12409 |
Ejemplares similares
-
Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
por: Nakazawa, Youya, et al.
Publicado: (2015) -
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
por: Matsuki, Masahiro, et al.
Publicado: (2018) -
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017) -
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014) -
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models
por: Ito, Ken, et al.
Publicado: (2014)